This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Our practice

Our Practice

The Deloitte Touche Tohmatsu (DTT) Life Sciences and Healthcare (LSHC) industry group with LSHC specialists from DTT member firms, is comprised of more than 5,400 professionals in over 47 countries. Their understanding of the industry’s challenges and their ability to quickly respond with integrated, comprehensive services put the DTT member firms in a unique position to help their clients. These professionals can help companies in their efforts to bring discoveries to life and to improve the quality of care while they create and sustain long-term, bottom-line profitability.

The Luxembourg firm has a team of professionals with broad industry expertise working in various fields within the life sciences and healthcare industry. It has recently been strengthened with additional life sciences and healthcare projects, in particular through projects in organisational, human capital and IT areas, for clients such as:

  • Centre Hospitalier de Luxembourg (CHL)
  • Entente des Hôpitaux Luxembourgeois (EHL)
  • Pfizer
  • Johnson&Johnson
  • Clinique Privée Dr E. Bohler
  • Fondation François-Elisabeth (FFE)
  • Croix Rouge Luxembourgeoise
  • Fondation Cancer
  • Fondation Kriibskrank Kanner
  • Steftung Hellef Doheem
  • Sanofi
  • Novasep
  • Agence eSanté
  • Novo Nordisk
  • GlaxoSmithKline

Strategic expertise in life sciences and healthcare

DTT member firms provide professional services to:

  • 81% of the life sciences and healthcare companies in the 2011 Fortune Global 500
  • Almost 80% of the life sciences and healthcare companies in the 2009 Fortune U.S. 100
  • All of the ten largest medical equipment manufacturers
  • All of the ten largest biotechnology companies
  • All of the ten largest pharmaceutical manufacturers
  • Leading public and private healthcare services entities and companies around the globe

Since January 2006 Deloitte & Touche GmbH Wirtschaftsprüfungsgesellschaft is the unique shareholder of Gebera - Gesellschaft für betriebswirtschaftliche Beratung mbH. For over 30 years Gebera has provided answers to challenges in the healthcare sector and the company has an extensive expertise in the hospital sector.

In July 2008, Recombinant Capital, Inc. was purchased by Deloitte LLP and is now known as Deloitte Recap LLC (Recap). Recap offers biopharmaceutical business intelligence subscription tools and consulting services tailored toward business development, corporate strategy, financial, legal, academic and R&D professionals. Recap recently launched a new series of biopharmaceutical business intelligence tools, the Recap IQ Series by Deloitte™, providing analytical tools to help life sciences companies leverage comprehensive biopharma alliance data, deal values and drug development histories to support the development of alliance and clinical development strategies.

In August 2011, Intrasphere, a leading consulting business in the areas of drug safety, signal intelligence, pharmacovigilance and regulatory information management, joined Deloitte. PharmaCM®, Intrasphere’s renowned content management platform for life sciences organisations which enables the clinical trial information registration process, is now available to Deloitte and their clients.

Economist Intelligence Unit An ongoing collaboration has been established with the Economist Intelligence Unit (EIU) for surveying life sciences executives on the future of the life sciences industry.
World Economic Forum A long-standing relationship is sustained with the forum’s healthcare governors group to analyse topics such as emerging markets issues and innovations in the area of healthcare.
Biotechnology Indutry Organization Deloitte is a long-standing member of the Biotechnology Industry Organization. Deloitte professionals participate as moderators and panellists at the annual BIO Convention, an event which is attended by more than 20,000 industry executives.
BioPartening Deloitte is a prominent sponsor of the BioPartnering Europe, an event that provides partnering and networking opportunities for decision-makers from leading biotechnology, pharmaceutical and investment companies from around the world through one-to-one partnering meetings, presentations, expert panels and exhibitions.
Forbes Forbes Insights is a new program for FY10 that will develop three spot surveys of current ‘top of mind’ industry topics related to life sciences and health care.
Financial Times The Financial Times — Deloitte is the lead sponsor of FT’s Pharmaceutical and Biotechnology Conference, one of Europe's pre-eminent industry events attended by leading executives, government decision-makers, investors, analysts and other specialist providers.
Health Information and Management Systems Society Health Information and Management Systems Society (HIMSS) — Deloitte is an active member of this leading industry organisation for the healthcare information technology sector.

 

Contact

  • Luc Brucher
    Partner - Healthcare Leader
  • Karine Pontet
    Directeur - Human Capital Advisory/Transformation

Related links

  • ExternalURL
  • ExternalURL
  • ExternalURL
  • ExternalURL

More Learn more

  • 2014 Global life sciences outlook | Whitepaper
    The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations.
  • Luxembourg: Un système de santé en évolution face à des défis majeurs | Whitepaper
    Savoir que l’on peut être soigné rapidement selon des normes de qualité élevées a toujours été au cœur des principales préoccupations collectives de nos sociétés modernes.
  • Etude Deloitte 2013 sur les consommateurs de soins de santé au Luxembourg | Whitepaper
    Similitudes, changements et nouveautés en matière d’attentes et de comportements des consommateurs de soins de santé face au système de santé luxembourgeois.
  • Étude 2011 sur les consommateurs de soins de santé au Luxembourg | Whitepaper
    Dans le présent rapport, nous vous proposons une analyse pouvant servir de référentiel à la consommation de soins de santé au Luxembourg.

Share

 

Stay connected:
Get connected
Share your comments
More on Deloitte Luxembourg
Learn about our site

Recently published